Drug Trial Radar · NCT07446270
Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies
Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Mar 3, 2026
Primary completion
Oct 30, 2027
Study completion Oct 30, 2028
Sponsor
- Lead sponsor
- Chinese PLA General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies
Conditions
- Treatment for Advanced Colorectal Cancer
- Treatment for Advanced Pancreatic Cancer
Interventions
Colorectal cancer: Tunlametinib + cetuximab βDrug
Colorectal cancer: Tunlametinib 6/9mg bid+ cetuximab β 500mg/m2
Pancreatic cancer: Tunlametinib + cetuximab βDrug
Pancreatic cancer: Tunlametinib 6/9mg+ cetuximab β 500mg/m2
Pancreatic cancer: Tunlametinib +NimotuzumabDrug
Pancreatic cancer: Tunlametinib 6/9mg bid +Nimotuzumab 400mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.